| Title |
Resveratrol inhibits the proliferation of A549 cells by inhibiting the expression of COX-2
|
|---|---|
| Published in |
OncoTargets and therapy, May 2018
|
| DOI | 10.2147/ott.s157613 |
| Pubmed ID | |
| Authors |
Xia Li, Fang Li, Fangfang Wang, Jinfeng Li, Cunzhi Lin, Jianxin Du |
| Abstract |
The aim was to investigate resveratrol effects on A549 cells proliferation. A total of 104 lung adenocarcinoma tissues and nontumor tissues were collected. BEAS-2B cells were cultured in RPMI 1640 medium (group A). A549 cells were treated with RPMI 1640 medium containing different resveratrol concentrations. A549 cells were transfected and grouped as follows: blank group, siRNA-negative control group, siRNA-COX-2 group and resveratrol + siRNA-COX-2 group. qRT-PCR and Western blot were conducted to detect COX-2 expression. MTT assay, soft agar clone assay and flow cytometry were performed to assess proliferation and cell cycle. The relative expression of COX-2 mRNA was significantly increased in lung adenocarcinoma tissues (P<0.01) and it was closely related with clinical stages. Resveratrol at 60 μmol/L significantly inhibited A549 cells proliferation, S phase cells proportion and COX-2 expression (P<0.01). COX-2 expression in siRNA-COX-2 group was significantly lower than that in blank group and siRNA-negative control group (P<0.01). OD570 values, colony formation rate and S phase cells proportion of resveratrol + siRNA-COX-2 group were much lower than those of other groups (P<0.01). Resveratrol inhibits A549 cells proliferation by inhibiting COX-2 expression. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 30 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 5 | 17% |
| Student > Ph. D. Student | 4 | 13% |
| Student > Master | 4 | 13% |
| Researcher | 3 | 10% |
| Unspecified | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 12 | 40% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 23% |
| Biochemistry, Genetics and Molecular Biology | 3 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
| Agricultural and Biological Sciences | 1 | 3% |
| Unspecified | 1 | 3% |
| Other | 2 | 7% |
| Unknown | 14 | 47% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 May 2018.
All research outputs
#16,053,755
of 25,382,440 outputs
Outputs from OncoTargets and therapy
#889
of 3,016 outputs
Outputs of similar age
#196,228
of 339,234 outputs
Outputs of similar age from OncoTargets and therapy
#38
of 95 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 339,234 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 95 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.